CD30, CD15, CD50, and PAX5 Expressions as Diagnostic Markers for Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL)
Mozaheb Z. Epiemology of Hodgkin’s lymphoma. Health. 2013;5:17-22.
Huh J. Epidemiologic overview of malignant lymphoma. Korean J Hematol. 2012;47:92-104.
Swerdlow AJ. Epidemiology of hodgkin’s disease and non-Hodgkin’s lymphoma. European Journal of Nuclear Medicine and Molecular Imaging. 2003;30:S3-12.
Devita VT, Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Annals of Internal Medicine. 1970;73:881–95.
National Cancer Institute. Cancer stat facts: Hodgkin Lymphoma. Downloaded from: https://seer.cancer.gov/statfacts/html/hodg.html
Data from Dharmais National Cancer Hospital Center.
Swerdlow SH, Campo E, Harris NL, et al, eds. WHO classification of tumours of the haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press;2008:157-334.
Petrella TJ, Michiels F, Michiels R. et al. CD 15 antigen in Hodgkin's disease. Pathol Res Pract 1989. 185:886–90.
Carbone A, Gloghini A, Volpe R. Paraffin section immunohistochemistry in the diagnosis of Hodgkin's disease and anaplastic large cell (CD30+) lymphomas. Virchows Arch A Pathol Anat Histopathol 1992. 420:527–32.
Eichenauer DA, Engert A, Dreyling M. ESMO Guidelines Working Group Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22:vi55-8.
Pireli SA., Ascani S., Leoncini L., et.al, Hodgkin’s lymphoma: the pathologist’s viewpoint. J Clin Pathol 2002;55:162–76
Park SJ., Kim S, Lee DH., et.al., Primary Systemic Anaplastic Large Cell Lymphoma in Korean Adults: 11 Years' Experience at Asan Medical Center. Yonsei Med J 2008; 49:601- 9
Wu SJ., Chen CY., Su IJ., et.al. Clinical Characteristics and Treatment Response of Hodgkin’s Lymphoma in Taiwan.,Formos Med Assoc 2008;107:4–12
Wang YF., Yang YL., Gao ZF., et.al., Clinical and laboratory characteristics of systemic anaplastic large cell lymphoma in Chinese patients. J Hematol Oncol. 2012; 5:38.
Schirmann T, Steinwand M., Wezlwer X., et.al. CD30 as a Therapeutic Target for Lymphoma. BioDrugs (2014) 28:181–209
Pierce JMR, Mehta A. Diagnostic, prognostic and therapeutic role of CD30 in Lymphoma. Expert Rev Hematol. 2017;10:29-37
Desouki MM., Post GR., Cherry D., et.al., Pax-5: A Valuable Immunohistochemical Marker in the Differential Diagnosis of Lymphoid Neoplasms. Clin Med Res. 2010; 8: 84–8.
Stein H., Foss HD., Durkop H., et.al., CD301 anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681-95.
- There are currently no refbacks.